Michel Spagnol Appointed President and CEO of Novasep
News Jun 27, 2013
Novasep has announced the appointment of Michel Spagnol as president and CEO of the company, effective from June 25, 2013.
He will succeed Patrick Glaser, who after three years at Novasep in France, has decided to return to the USA.
Michel Spagnol joins Novasep from Shasun, where he was president and chief technology officer. He is a proven business leader with core expertise in leading contract manufacturing of active pharmaceutical ingredients.
More broadly, he has strong experience in using and developing innovative technologies to address the needs of customers in fine chemicals and life sciences fields.
Prior to Shasun, Michel Spagnol spent his career at Rhodia in Lyon, France and Cranbury, NJ, USA where he progressed first in technical R&D leadership roles and subsequently transitioned to business development as sales and marketing vice president of Rhodia Pharma Solutions.
Over the past months, Novasep’s growth has gained momentum with significant new investments in Mourenx, France, to build the world’s largest chromatography plant dedicated to the pharmaceutical industry; in Le Mans, France, to expand manufacturing capabilities of cutting-edge anti-cancer therapies and in Shanghai, China, to better serve its clients in Asia.
Roger-Marc Nicoud, founder and non-executive chairman of the board of Novasep, said: “We are delighted to welcome Michel Spagnol to Novasep as CEO. His track record in delivering customer driven solutions, his international and scientific background coupled with his extensive management experience, longstanding knowledge and relationships in the pharmaceutical industry will be strong assets for the company. He has all the qualities required to consolidate and accelerate Novasep’s development. On behalf of the board, I would like to thank Patrick Glaser for his contributions as the CEO of the company and accomplishments as head of Novasep Synthesis. Over the past years, Novasep has grown significantly under his leadership and he has developed a solid foundation for Michel Spagnol to build upon.”
Michel Spagnol, the new CEO, said: “Novasep is a world leader in purification technologies with differentiated capabilities in hazardous chemistry and high potency chemistry. It is well positioned to serve the pharmaceutical, fine chemical, bio-pharma and industrial biotech industries. I am very pleased to be given the opportunity to lead the company. I am looking forward to working closely with all my new colleagues. Novasep is on the right track for continued growth and expansion with promising projects which will enable us to continue delivering value-added solutions for our global customers.”
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE